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Abstract
Purpose—Women who smoke at breast cancer diagnosis have higher risk of breast cancer-
specific and all-cause mortality than non-smokers; however, differences by ethnicity or prognostic 
factors and risk for non-cancer mortality have not been evaluated.
Methods—We examined associations of active and passive smoke exposure with mortality 
among Hispanic (n=1,020) and non-Hispanic White (n=1,198) women with invasive breast cancer 
in the Breast Cancer Health Disparities Study (median follow-up of 10.6 years).
Results—Risk of breast cancer-specific (HR=1.55, 95% CI:1.11-2.16) and all-cause (HR=1.68, 
95% CI:1.30-2.17) mortality was increased for current smokers, with similar results stratified by 
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ethnicity. Ever smokers had an increased risk of non-cancer mortality (HR=1.68, 95% CI:
1.12-2.51). Associations were strongest for current smokers who smoked ≥20 years, were 
postmenopausal, overweight/obese, or reported moderate/high alcohol consumption; however, 
interactions were not significant. Breast cancer-specific mortality was increased 2-fold for 
moderate/high recent passive smoke exposure among never smokers (HR=2.12, 95% CI:
1.24-3.63).
Conclusions—Findings support associations of active and passive smoking diagnosis with risk 
of breast cancer-specific and all-cause mortality, and ever smoking with non-cancer mortality, 
regardless of ethnicity and other factors. Smoking is a modifiable lifestyle factor and effective 
smoking cessation and maintenance programs should be routinely recommended for women with 
breast cancer.
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INTRODUCTION
Despite improvements in early detection and treatment, breast cancer remains the second 
leading cause of cancer death for women in the US, and survival rates vary by age and race/
ethnicity (1). It is important to identify modifiable lifestyle factors that contribute to breast 
cancer-specific mortality. Cigarette smoking is a leading preventable factor for all-cause 
mortality. Scientific evidence demonstrates that there is no safe level of cigarette smoke 
exposure, which has been linked to nearly one-third of all cancer deaths (2). Cigarette smoke 
contains more than 70 carcinogens that can be metabolically activated and transported to 
breast tissues leading to DNA damage, disruption in estrogen metabolism, and 
carcinogenesis (2).
While biologically plausible mechanisms exist by which active and passive cigarette smoke 
may induce or promote breast cancer (3), the association with breast cancer-specific 
mortality is not well established. Cigarette smoke is reported to induce epithelial to 
mesenchymal transition (4), increase metastatic potential of breast cancer cells to lymph 
nodes (5) and lungs (6, 7), influence aggressive tumor behavior (8, 9), and is associated with 
later disease stage (10), all of which adversely affect breast cancer prognosis, lower quality 
of life (11) and increase risk of all-cause mortality (12-16). Data for breast cancer-specific 
mortality, however, are inconsistent, with reports of positive (12, 17-23) or no (13, 24-28) 
associations. No associations have been found between passive smoke exposure and breast 
cancer-specific mortality (27, 29-31). Several studies have evaluated whether prognostic 
factors, including disease stage and body mass index (BMI) (12, 13, 16, 22, 23), modify the 
association of smoking with breast cancer-specific mortality, but results are conflicting. 
Moreover, no studies have evaluated whether smoking is associated with survival 
differences between Hispanic and non-Hispanic White (NHW) women with breast cancer. 
Risk of breast cancer-specific mortality differs between Hispanic and NHW women; 
associations for higher (32, 33) and reduced (34) risk have been reported. Although 
Hispanics reportedly have lower smoking rates (35) they are a genetically admixed 
population with varying proportions of Native American (NA) ancestry and we previously 
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reported that ethnic differences in genetic factors may influence susceptibility to carcinogens 
in cigarette smoke (36).
We examined whether smoking is associated with death due to breast cancer and other 
causes in NHW and Hispanic/NA women included in the Breast Cancer Health Disparities 
Study (BCHDS). We also examined potential effect modification of active and passive 
smoke exposure and breast cancer-specific mortality by ethnicity and other factors 
associated with breast cancer survival.
MATERIALS AND METHODS
Study population
The BCHDS includes participants from three population-based case-control studies: 4-
Corners Breast Cancer Study (4-CBCS) (37); San Francisco Bay Area Breast Cancer Study 
(SFBCS) (38); and Mexico Breast Cancer Study (MBCS) (39). The BCHDS methods have 
been previously described (40). Briefly, in-person interviews were conducted and 
anthropometric measurements and blood/saliva samples collected using standard protocols, 
and data were harmonized across studies. The analyses were restricted to histologically 
confirmed first primary invasive breast cancer cases from 4-CBCS (NHWs, Hispanic/NAs) 
and SFBCS (Hispanics), since no survival data were available for MBCS. The 4-CBCS 
included women ages 25-79 years diagnosed between 10/1999-05/2004 in Arizona, 
Colorado, New Mexico, or Utah. The SFBCS included women ages 35-79 years from the 
San Francisco Bay Area (Hispanics, NHWs, and African Americans diagnosed between 
04/1995-04/1999; and Hispanics diagnosed from 5/1999-4/2002). In SFBCS, smoking data 
were collected only for Hispanic cases diagnosed from 1999-2002. Data on survival and 
smoking were available for 1,860 4-CBCS cases and 417 SFBCS cases. Participants signed 
informed written consent prior to participation. Studies were approved by their 
corresponding Institutional Review Boards.
Exposure assessment
Smoking measures included: ever smoking (≥100 cigarettes with at least one cigarette/day 
for ≥six months), never, current, or former smoking during the referent year (calendar year 
pre-diagnosis); intensity (cigarettes/day); duration (years smoked); pack-years (intensity 
times duration); and recency (years since quitting for former smokers). Passive smoke 
exposure, collected in 4-CBCS only, was defined as the number of hours/week exposed both 
inside and outside the home during the referent year and at ages 15, 30, and 50 years. Long-
term passive smoke exposure was based on average exposure at ages 15 and 30 years and 
during the referent year for women aged <50 years; and at ages 15, 30, and 50 years and 
during the referent year for women aged ≥50 years (36).
Covariates
Women who reported having periods during the referent year were classified as 
premenopausal. Women were considered postmenopausal if they reported a natural 
menopause, taking hormone therapy, or still having periods but were above the 95th 
percentile of age for ethnicity of those who reported having a natural menopause within their 
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study center. BMI was calculated as self-reported weight (kg) during the referent year, 
divided by measured height squared (m2). Grams of alcohol intake was based on self-
reported consumption over the lifetime, with the exception of a subset of SFBCS cases for 
whom it was consumption during the referent year. Physical activity was based on hours of 
vigorous intensity activity/week during the referent year. Education was categorized as 
completion of high school or less or some college/graduate school. Ethnicity was based on 
self-report in both studies; a few women self-identified as NA and were combined with 
Hispanic women (37). NA ancestry was based on 104 ancestry informative markers to 
distinguish European and NA ancestry (40), genotyped using a multiplexed bead array assay 
(GoldenGate chemistry, Illumina, San Diego, California) following Whole Genome 
Amplification.
Tumor characteristics and survival
Statewide cancer registries provided information on disease stage, ER/PR status (determined 
by diagnosing pathologists), months of survival post-diagnosis, and primary cause of death. 
Survival data were through December 2011 for Utah, Colorado, and California, and through 
2010 for Arizona and New Mexico. Surveillance Epidemiology and End Results (SEER) 
summary disease stage was categorized as local, regional, or distant.
Statistical analysis
Genetic admixture, the proportion of an individual’s genome originating from one of two 
original founding populations (European and NA), was inferred using STRUCTURE 2.0, a 
multilocus genetic model-based clustering algorithm (41). Categorization of NA ancestry 
was based on the distribution of NA ancestry in control women (40). Two categories were 
used for the present analyses: low (<29%) versus moderate/high (≥29%). Descriptive 
statistics were calculated for potential confounders: t-tests and chi-square tests were used to 
compare smoking status categories. Other smoking measures were defined as cigarettes/day 
(<20, ≥20); duration (<20, ≥20 years); pack-years (<20, ≥20, <35, ≥35); recency (<20, ≥20 
years); and passive smoke exposure hours: average long-term (none, low (1-8), moderate/
high (>9)), and recent (none, low (1-10), moderate/high (>10)). Passive smoke exposure 
categories were based on distribution of exposure hours and events; three strata best fit the 
data and allowed sufficient power for assessing associations.
Associations between smoking and breast cancer-specific, non-cancer, and all-cause 
mortality were evaluated using multivariable Cox proportional hazards models (PHREG). 
Hazard ratios (HR) and 95% confidence intervals (CI) were estimated with months post-
diagnosis as the time scale with the following referent groups: never smokers for active 
smoking analyses and no active/no passive smokers for passive smoking analyses. 
Covariates were retained in the final models for the three mortality outcomes if in the breast 
cancer-specific analysis the univariable p-values were ≤0.20, and if adjustment produced a 
change of ≥10% in the HR for smoking, allowing for direct comparison of results across all 
analyses. Age and study center were matching variables and included in all models. Physical 
activity, menopausal status, NA ancestry, and ER/PR status were excluded from final 
models. Participants were censored if they were lost to follow-up; or died of causes not 
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related to the outcomes. Those with unspecified cause of death were censored at death date; 
sensitivity analysis indicated that their inclusion did not meaningfully alter estimates.
For breast cancer-specific mortality, likelihood-ratio tests were used to assess two-way 
interactions between current smoking and ethnicity, NA ancestry, menopausal status, 
overweight/obese (BMI <25, ≥25 kg/m2), ER/PR status (positive, negative), disease stage 
(local, regional/distant), long-term alcohol consumption (none/low <5gm/day, moderate/
high ≥5gm/day), and time since diagnosis (≤5, >5 years). ‘Time since diagnosis’ describes 
the short (0-5 years) and long-term (5+ years) survival by smoking status post-diagnosis. 
Chi-square (X2) test Wald-p-values for interaction terms are reported. An adjusted breast 
cancer survival curve, based on PHREG model estimates of the survival function for 
ethnicity and smoking status was plotted. P-values or p-trend <0.05 were deemed 
statistically significant. The proportional hazards assumption was tested graphically and 
statistically using an interaction of main effects and covariates with the log of survival time 
(42). All analyses, with the exception of all-cause mortality, met the proportional hazards 
assumption. Age and stage appeared to be time dependent; therefore models for all-cause 
mortality that included time interaction terms for both were evaluated. Differences between 
the models with the additional time interaction terms and standard model were not 
meaningful; hence, we present only the results from the more widely used models. Analyses 
were based on 2,218 invasive cases (4-CBCS n=1,812; SFBCS n=406) with complete 
exposure data for significant covariates and active smoking, and 1,804 (4-CBCS only) for 
passive smoke exposure. Statistical analyses were performed using SAS version 9.3 (SAS 
Institute, Cary, NC).
RESULTS
Approximately 60% of cases were never smokers, 26.8% were former smokers, and 13.4% 
were current smokers (Table 1). A higher proportion of current smokers were younger 
(mean 52.6 years) at diagnosis compared to never (mean 54.5 years) and former (mean 56 
years) smokers; reported higher long-term alcohol consumption (34.9% vs. 12.8% and 
30.6%, respectively); were less likely to be overweight/obese (54.7% vs. 66.3% and 60%, 
respectively); and were deceased by the end of follow-up (27.8% vs. 18.9% and 18.7%, 
respectively). Hispanic/NA women reported never smoking (66.1%) more frequently than 
NHW women (54%). Passive smoke exposure was reported by 48% of current, 32% of 
former, and 15% of never smokers. The median follow-up for all women was 10.6 years. Of 
445 deaths, 243 (54.6%) were attributable to breast cancer (60.1% never; 19.7% former; and 
20.2% current smokers).
Mortality outcomes: ever smokers
Risk of breast-cancer-specific (HR=1.55, 95% CI:1.11-2.16) and all-cause (HR=1.68, 95% 
CI:1.30-2.17) mortality was significantly increased for current compared to never smokers 
(Table 2). Non-cancer mortality (HR=1.68, 95% CI:1.12-2.51) was significantly increased 
among ever smokers. No significant associations were observed for smoking intensity and 
duration among ever smokers with breast cancer-specific mortality. Risk of non-cancer 
mortality was significantly increased for women who smoked ≥20 cigarettes/day (HR=1.86), 
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≥20 years (HR=1.79), or ≥35 (HR=2.46) pack-years. Similarly, all-cause mortality was 
significantly higher for women who smoked ≥20 years (HR=1.47) and ≥35 pack-years 
(HR=1.82). Although risk of breast cancer-specific mortality was reduced among those who 
quit ≥20 years prior to their diagnosis, the association was not significant due to small 
numbers (n=16).
Mortality outcomes: current smokers
Breast cancer-specific mortality was significantly increased among current smokers who 
smoked ≥20 years (HR=1.60, 95% CI:1.11-2.30) or <20 cigarettes/day (HR=1.69, 95% CI:
1.14-2.50) (Table 3). Breast cancer-specific mortality differed between ethnic and smoking 
status groups (p=0.01); however, none of the pair-wise comparisons were statistically 
significant after adjustment for multiple comparisons (Figure 1). When stratified, both NHW 
and Hispanic/NA current smokers had an increased risk of breast cancer-specific mortality 
(HR=1.51 and HR=1.58, respectively), although results were non-significant (Table 4). 
Results were similar by proportion of NA ancestry. Stronger associations were found among 
current smokers who were postmenopausal (HR=1.65, 95% CI:1.02-2.64), overweight/obese 
(HR=1.74, 95% CI:1.13-2.69), moderate/high alcohol consumers (HR=2.91, 95% CI:
1.37-6.18), and >5 years post-diagnosis (HR=1.75, 95% CI:1.12-2.72) (Table 4). There were 
no significant interactions for any of these factors or tumor characteristics (Table 4).
Mortality outcomes: passive smokers
Moderate/high passive smoke exposure during the referent year was significantly associated 
with breast cancer-specific mortality among all women (HR=1.54 95% CI:1.04-2.26) and 
never smokers (HR=2.12 95% CI:1.24-3.63), and all-cause mortality among never smokers 
(HR=1.83, 95% CI:1.17-2.88) (Table 2). The associations between long-term passive 
exposure and breast cancer-specific, all-cause, and non-cancer mortality were non-
significant.
DISCUSSION
Our results suggest that women who smoked regularly at the time of breast cancer diagnosis 
had a significantly increased risk of breast cancer-specific (HR=1.5) and all-cause (HR=1.6) 
mortality compared to women who never smoked. Breast cancer-specific mortality was 
significantly higher among current smokers who reported smoking for ≥20 years (HR=1.6). 
Hispanic/NA and NHW women had comparable elevated risk estimates. Although 
interactions were not statistically significant, the association of current smoking with breast 
cancer-specific mortality was stronger among women who were postmenopausal, 
overweight/obese, and long-term alcohol consumers.
The lack of association between ever smoking and breast cancer-specific mortality agrees 
with Calle et al (18), but contrasts with three studies reporting increased risk (HR range:
1.26-1.40) (16, 27, 43). We found a positive association between ever smoking and all-cause 
mortality, similar to previous reports (14, 16). We also observed a significant relationship 
between increasing pack-years of smoking and non-cancer mortality, similar to a previous 
report (23). While a positive association between current smoking and death from ‘other 
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causes’ was reported previously, other cancers were included as events (12, 23). Smoking 
affects CVD and pulmonary mortality by impairing immune function and exacerbating 
comorbid conditions (2). It is unclear whether these pathways affect breast cancer survival 
also (25).
Six studies have reported that current smoking is associated with risk of breast cancer-
specific mortality (12, 18-23), in which the prevalence of current smoking varied from 4.6% 
(28) to 39.5% (23), and mean follow-up time was ≥5 years. Also, the proportion of deaths 
ranged widely from 0.15% (18) to 45.3% (25). In the present study, 13.4% (n=298) of 
women reported current smoking and 16.4% (n=49) of them died of breast cancer. A recent 
meta-analysis (17), reported a significant summary estimate for breast cancer-specific 
mortality for current smokers (HR=1.33, 95% CI:1.12-1.58) (12, 13, 16, 19, 21, 22, 24, 25, 
27). Additionally, several studies have reported an association between current smoking and 
all-cause mortality (12, 13, 17, 20, 22-25) with estimates ranging from 1.16 (25) to 2.63 
(12).
We did not find an association between former smoking and risk of breast cancer-specific 
mortality, possibly due to reduced power or to behavioral changes that decreased mortality 
risk. Few studies have reported a significant association, even considering time from 
cessation to diagnosis (20, 24, 26, 28). Results are conflicting, with HRs ranging from 0.46 
in British (24) to 4.79 in Japanese (26) women. However, Pierce et al. (20) found a dose-
response relationship, with the highest risk of death associated with ≥35 pack-years of 
smoking (HR=1.61, 95% CI: 1.28-2.03), and Saquib et al. (28) reported an increased risk 
among those who had smoked ≥20 pack-years (HR=1.62, 95% CI:1.11-2.37).
Some previous studies reported increased risk of breast cancer death among smokers who 
were premenopausal (12, 22), had ER positive tumors (12, 13), were older at diagnosis (16), 
or overweight/obese (12, 13, 23). The increased risk in current smokers who were 
overweight/obese, postmenopausal could be due to increased bioavailable estrogen and 
IGF-1, which stimulate cell proliferation (44). Increased risk in moderate/high alcohol 
consumers could be due to interference with estrogen pathways via ethanol metabolism (45). 
Synergistic effects on mortality in these subgroups are therefore plausible.
It has been suggested that including women exposed to passive smoke in the never smoking 
referent group attenuates risk estimates (46). We compared results for analyses using a no 
active smoking vs. a no active/no passive smoking referent group. HRs for current smoking 
with breast cancer-specific and all-cause mortality increased by only 12% and 6%, 
respectively, when based on a no active/no passive smoking referent group. However, CIs 
overlapped and statistical power was reduced due to the use of a smaller referent group 
(n=321) (3). Moreover, women who have never been exposed to passive smoke may differ 
in many ways from those who have been exposed.
Four reports (27, 29-31) evaluating the relationship between passive smoke exposure and 
breast cancer-specific mortality reported no significant associations with a spouse who 
smoked, exposure in the home or workplace, or by intensity and duration; however, none 
evaluated passive smoke exposure at multiple time periods to estimate lifestyle exposure. 
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We found a significant association of breast cancer-specific mortality with recent passive 
smoke exposure, but not with average long-term exposure. However, we did not have data 
for exposure source, duration, dosage, or changes in intensity over time, which could 
measure cumulative exposure to passive smoking, as included in the 2014 Surgeon 
General’s Report (3) and 2007 California Environmental Protection Agency Report (46).
Smoking may affect breast cancer-specific mortality by several mechanisms. Compounds 
contained in cigarette smoke reach breast tissue and activate genotoxic metabolites that 
damage DNA, form DNA adducts, disrupt hormone metabolism, and impair immune 
function (2). Cigarette smoke may influence the metastatic potential of cancer cells, cell 
adhesiveness, and stimulate tumor angiogenesis and growth. Smoking is associated with less 
favorable prognostic markers that affect tumor behavior (5-8), including increased frequency 
and larger metastases to lymph nodes and lungs (5-8), increased risk for ER/PR negative 
tumors (9), and regional stage disease (10). Pierce et al. recently reported that former and 
current smoking increases risk of breast cancer recurrence by 37% and 41%, respectively 
(20). Similarly, Bishop and colleagues found that recurrence was 6.7 times higher for 
current smokers at the time of a partial mastectomy and radiation therapy compared to 
nonsmokers (47). Furthermore, Peppone et al. found that smoking is associated with a 
higher symptom burden during and after treatment, which may influence completion of 
treatment regimens (48).
This study has some limitations. Smoking exposure was limited to prior to diagnosis with no 
follow-up for change in status. Data were self-reported with potential recall bias. Statistical 
power was limited for detection of effect modifiers further categorized by smoking intensity 
and duration. Thirty-five percent of cases were missing smoking data, however 99.6% of 
these were SFBCS participants (diagnosed between 1995-1999) who were not asked about 
smoking habits, suggesting less potential for differential bias than if they had refused to 
respond. Data for treatment, mode of detection, tumor characteristics (lymph node 
involvement, histological grade, HER2/neu status), response to treatment, and screening 
history by smoking status were unavailable. It is possible that current smokers received less 
aggressive, interrupted/incomplete treatments because of poor general health (48), which 
can differently impact survival outcomes and findings should be interpreted with caution. 
We were, however, able to evaluate multiple other covariates including demographic, 
behavioral, and tumor prognostic markers such as stage and ER/PR status.
There are several strengths to our study. This study is the first to evaluate whether 
associations between smoking and breast cancer-specific mortality differ by Hispanic/NA 
and NHW ethnicity and by proportion of NA ancestry. We had a relatively long follow-up 
time (median=10.6 years); thus, our analyses included women with local and regional stage 
disease, while studies with shorter follow-up (5-6 years) mainly reflect mortality in women 
with distant stage disease. We ascertained vital status from state-wide tumor registries and 
the National Death Index, which reduced potential misclassification of cause of death. We 
were able to evaluate passive smoke exposure inside and outside of the home for various 
ages in the subset of women from 4-CBCS; although, there is potential recall bias of passive 
smoke exposure at age of 15 among a mostly postmenopausal group. Lastly, while other 
Boone et al. Page 8













studies use the definition ‘100 cigarettes in a lifetime’, we defined regular use of cigarettes 
as ‘at least 1 cigarette/day for 6 months or longer.’
Our results strongly suggest that active and passive smoking around the time of breast 
cancer diagnosis is associated with increased risk of breast cancer-specific and all-cause 
mortality. A history of ever smoking is associated with increased risk of non-cancer 
mortality, which is primarily attributed to cardiovascular and pulmonary diseases. Lastly, 
the association between current smoking and breast cancer-specific mortality did not differ 
by ethnicity, which suggests that smoking does not explain differences in breast cancer 
survival observed between NHW and Hispanic/NA women. More research is needed on the 
association of smoking with breast cancer-specific mortality in ethnically diverse 
populations and subgroups, and how changes in smoking habits following diagnosis impact 
breast cancer outcome. Ten to 20% of women smoke post-breast cancer diagnosis (49, 50), 
with the highest proportion (43%) among women aged 18-40 years (50). Smoking at breast 
cancer diagnosis is a major modifiable risk factor for poorer outcomes, and effective 
smoking cessation and maintenance programs should be routinely recommended for women 
with breast cancer.
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Figure 1. Adjusted breast cancer survival by ethnicity and cigarette smoking status
Log-rank p-value=0.01; Wald p=0.01; Adjusted for age, study, body mass index, stage, 
alcohol consumption, and education
Sidak multiple comparisons adjusted Log-rank pair-wise p-values: Within Hispanic women: 
current vs. former, p= 0.22; current vs. never, p=0.99; former vs. never, p= 0.99.
Within non-Hispanic women: current vs. former, p= 0.10; current vs. never, p=0.96; former 
vs. never, p= 0.99
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Table 1
Study Characteristics by Smoking Status among Women Diagnosed with Invasive Breast Cancer, the Breast 
Cancer Health Disparities Study.
All women Never smokers Former smokers Current smokers
n=2,218 n=1,325 (59.7%) n=595 (26.8%) n= 298 (13.4%) p-value
a
Median follow-up, years, IQR
b 10.6 3.4 10.6 3.2 10.7 3.3 10.4 4.4 0.26
Age at diagnosis, mean, SD 54.5 11.0 54.2 11.2 56 10.7 52.6 10.2 <0.0001
Study, n %
  4-CBCS 1812 81.7 1057 79.8 508 85.4 247 82.9
0.03
  SFBCS 406 18.3 268 20.2 87 14.6 51 17.1
Self-reported ethnicity, n %
  NHW 1198 54.0 651 49.1 372 62.5 175 58.7
<0.0001




  Low 1055 47.6 593 44.8 319 53.6 143 48.0
<0.0001
  Moderate/High 671 30.2 464 35.0 133 22.4 74 24.8





  Premenopausal 815 36.7 501 37.8 200 33.6 114 38.3
0.54
  Postmenopausal 1372 61.9 803 60.6 391 65.7 178 59.7
  Missing 31 1.4 21 1.6 4 0.7 6 2.0
Body mass index, kg/m2, n %
  <25 820 37.0 447 33.7 238 40.0 135 45.3
<0.0001
  ≥25 1398 63.0 878 66.3 357 60.0 163 54.7
Education, n %
  High school or less 930 41.9 574 43.3 224 37.7 132 44.3
0.50
  Some college/graduate school 1288 58.1 751 56.7 371 62.4 166 55.7
Alcohol consumption n %
  None/Low 1762 79.4 1155 87.2 413 69.4 194 65.1
<0.0001
  Moderate/High 456 20.6 170 12.8 182 30.6 104 34.9
Passive smoke exposure hours
e
  None 377 17.0 321 24.2 41 6.9 15 5.0
  Low 526 23.7 341 25.7 133 22.3 52 17.4
<0.0001
  Moderate 468 21.1 241 18.2 167 28.1 60 20.1
  High 433 19.5 154 11.6 161 27.1 118 39.6
  Missing 414 18.7 268 20.2 93 15.6 53 17.8
Time since diagnosis, n %
  ≤5 years 274 12.3 155 11.7 77 12.9 42 14.1
0.21
  >5 years 1944 87.7 1170 88.3 518 87.1 256 85.9
Stage, n %
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All women Never smokers Former smokers Current smokers
n=2,218 n=1,325 (59.7%) n=595 (26.8%) n= 298 (13.4%) p-value
a
  Local 1403 63.3 821 62.0 397 66.7 185 62.1
  Regional 787 35.5 485 36.6 191 32.1 111 37.3 0.31




  Positive 1372 61.9 826 62.3 356 59.8 190 63.8
0.63
  Negative 408 18.4 246 18.6 113 19.0 49 16.4




  Positive 1198 54.0 726 54.8 310 52.1 162 54.4
0.81
  Negative 582 26.2 346 26.1 159 26.7 77 25.8
  Missing 438 19.7 253 19.1 126 21.2 59 19.8
Vital status, n %
  Alive 1773 79.9 1074 81.1 484 81.3 215 72.2
0.005
  Deceased 445 20.1 251 18.9 111 18.7 83 27.8
Cause of deathg, n %
  Breast cancer 243 54.6 146 58.2 48 43.2 49 59.0
  Other cancer 54 12.1 27 10.8 14 12.6 13 15.7
0.99
  Non-cancer 102 22.9 52 20.7 37 33.3 13 15.7
  Unspecified 46 10.3 26 10.4 12 10.8 8 9.6
Abbreviations: 4-CBCS- 4-Corners Breast Cancer Study; ER-Estrogen receptor; PR-Progesterone receptor; SFBCS-San Francisco Bay Area Breast 
Cancer Study. Note: column percentages may not total 100% due to rounding.
a
For tests of differences by cigarette status, p-value from t-tests for continuous variables and Mantel-Haenszel Chi square p-values for categorical 
variables are reported.
b
Chi-square p-value was derived using a non-parametric Kruskal-Wallis test to evaluate differences in the median follow-up times
c
Data for Native American ancestry are available for 1,726 of the 2,218 cases included in this analysis.
d
Data for menopausal status are available for 2,187 of the 2,218 cases included in this analysis.
e
Exposure to passive smoke is based on data available from 4-CBCS for 1,804 of the 2,218 cases included in this analysis; this variable captures 
long-term exposure to passive smoke and was based on the average of exposure hours/week reported for ages 15 and 30 years and during the 
referent year for women <50 years of age; and at ages 15, 30, and 50 years and during the referent year for women ≥50 years of age.
f
Data for ER/PR status are available for 1,780 of the 2,218 cases included in this analysis.
g
Non-cancer deaths included: cardiovascular diseases (CVD) (32%); pulmonary diseases (21%); renal failure/kidney diseases (9%); diabetes-
related illnesses (7%); and other conditions (31%).
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Table 3
Risk of Breast Cancer-specific Mortality Stratified by Smoking Intensity and Duration among Current 
Smokers, the Breast Cancer Health Disparities Study.
Breast cancer-specific mortality
Events Total HRa 95% CI
Never smokers 146 1325 1.00 Referent
Current smokers 49 298 1.55 1.11, 2.16
 Cigarettes/day
  <20 33 176 1.69 1.14, 2.50
  ≥20 16 121 1.31 0.77, 2.22
 Duration, years
  <20 8 47 1.33 0.64, 2.76
  ≥20 41 250 1.60 1.11, 2.30
 Pack-years
  <20 25 133 1.52 0.98, 2.37
  ≥20 22 157 1.44 0.90, 2.29
a
Adjusted for age, study, ethnicity, stage, body mass index, alcohol consumption, and education.
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Table 4
Risk of Breast Cancer-specific Mortality among Current Smokers Stratified by Socio-demographic and 
Prognostic Factors, the Breast Cancer Health Disparities Study.
Never Smokers Current vs. Never Smokers





  NHW 70 651 29 175 1.51 0.96, 2.38 0.98
  Hispanic/NA 76 674 20 123 1.58 0.94, 2.64
Native American ancestry
  Low 57 593 21 143 1.49 0.88, 2.52 0.92
  Moderate/High 47 464 13 74 1.69 0.87, 3.27
Menopausal status
  Premenopausal 67 501 20 114 1.41 0.82, 2.42 0.89
  Postmenopausal 76 803 26 178 1.65 1.02, 2.64
Body mass index, kg/m2
  <25 48 447 21 135 1.33 0.77, 2.29 0.44
  ≥25 98 878 28 163 1.74 1.13, 2.69
Alcohol consumption
  None/Low 134 1155 31 194 1.36 0.91, 2.02 0.15
  Moderate/High 12 170 18 104 2.91 1.37, 6.18
Time since diagnosis
  ≤5 years 69 155 19 42 1.40 0.79, 2.48 0.68
  >5 years 77 1170 30 256 1.75 1.12, 2.72
SEER Summary Stage
  Local 47 821 17 185 1.66 0.94, 2.94 0.85
  Regional/Distant 99 504 32 113 1.53 1.00, 2.34
ER status
  Negative 34 246 10 49 1.58 0.75, 3.30 0.86
  Positive 85 826 29 190 1.55 1.00, 2.42
PR status
  Negative 43 346 16 77 1.72 0.94, 3.15 0.31
  Positive 76 726 23 162 1.38 0.85, 2.26
Abbreviations: SEER-Surveillance Epidemiology & End Results; ER-Estrogen receptor; PR-Progesterone receptor
a
Adjusted for age, study, ethnicity, stage, body mass index, alcohol consumption, and education. When modification by a specific factor was 
evaluated, that factor was not included as a covariate in the multivariable model;
b
p -value for interaction term. P-values for likelihood ratio tests (difference in Chi-square test statistics for the models) were not significant.
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